Novartis in New Agreement With BioNTech to Help Manufacture Covid-19 Vaccine
October 21 2021 - 12:58AM
Dow Jones News
By Cecilia Butini
Novartis AG said Thursday that it has signed a new agreement
with BioNTech SE to support the production of the company's and
Pfizer Inc.'s Covid-19 vaccine at one of its facilities.
The Swiss pharma major said it will support the fill-and-finish
operations of the vaccine, meaning the transfer of the vaccine
substance into vials under sterile conditions.
It will do so at its facility in Ljubljana, Slovenia, and will
begin operations in the first half of 2022, Novartis said. At least
24 million vaccine doses will be filled there, the company
said.
The agreement follows another one which was signed earlier this
year and which had Novartis filling and finishing more than 50
million doses at its site in Stein, Switzerland.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 21, 2021 01:43 ET (05:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024